Abstract Background and Objective The most recently approved biologics for moderate-to-
severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently …

Abstracts Background and objective Biologics have revolutionized the management of
plaque psoriasis and are flourishing. We aimed to construct a knowledge structure in this …

Background/Objectives: Implementing model-informed precision dosing (MIPD) strategies
guided by population pharmacokinetic/pharmacodynamic (PK/PD) models could enhance …

Background The advent of biosimilars may increase the frequency of dose escalation with
biologics in psoriasis. Objective To explore the frequency and outcomes of dose escalation …

Interleukin-17A therapeutic inhibitors are among the most effective treatment methods for
moderate-to-severe plaque psoriasis (PP). Reflectance confocal microscopy is a non …

Background/Objectives: Patient care and control of inflammatory disorders, such as
psoriasis, can be improved by model-informed precision dosing (MIPD) techniques based …

SERENA is an ongoing European noninterventional longitudinal study evaluating retention,
effectiveness, safety, and quality of life (QoL) in secukinumab‐treated patients with active …

Abstract Background SB5 (adalimumab-bwwd) is an adalimumab biosimilar targeting tumor
necrosis factor (TNF) for the treatment of chronic inflammatory diseases, including moderate …

Background It is unknown whether the pre‐biologic treatment journey affects subsequent
biologic drug survival. Objective To examine the potential impact of a complex treatment …

Patients receiving interleukin (IL)‐inhibiting biologics for moderate‐to‐severe psoriasis
(PsO) may be treated with escalated doses to optimize outcomes. This study evaluated …